Fintel reports that on April 9, 2025, Guggenheim initiated coverage of Humana (NYSE:HUM) with a Buy recommendation. Analyst Price Forecast Suggests 4.77% Upside As of April 2, 2025, the average ...

Humana's stock has shown resilience, boosted by a 5% increase in Medicare Advantage payments. Read my analysis of HUM stock.

The healthcare stock at just under $282 per share and had been as much as 17% higher at the open, but till held onto most of ...

The 2024 Impact Report showcases Humana's impacts on communities, the dedication of employees and leaders, and how Humana is improving health outcomes through innovation and integrated care. The ...

Mizuho raised the firm’s price target on Humana (HUM) to $316 from $305 and keeps an Outperform rating on the shares. The firm surveyed 215 ...

Guggenheim analyst Jason Cassorla initiated coverage of Humana (HUM) with a Buy rating and $326 price target The firm launched coverage on 11 ...

Chip stocks rallied midday Tuesday, with Broadcom (AVGO) getting a particular boost after it authorized a $ ...

The U.S. stock market is careening through a second straight day of stunning swings Tuesday as uncertainty reigns about what ...

The Centers for Medicare & Medicaid Services projects a 5.06% increase in payments, driven by new data on fee-for-service ...

Health insurance stocks extended Monday’s gains into Tuesday after Medicare regulators finalized stronger-than-expected 2026 ...

The 5.1% benchmark increase is the largest in the past decade. The hike reflects more recent data capturing cost growth, ...

No big change is behind the move back upward, and analysts say more swings up and down are likely for markets in not only the days but also the hours ahead.